Moreover, a new phase III trial is underway evaluating chemotherapy (CAPOX or mFOLFOX6) and pembrolizumab, with or without zolbetuximab, as first-line therapy in advanced or metastatic GC/GEJC whose tumors are HER2-negative, CLDN18.2-positive, and PD-L1-positive (NCT06901531). This evidence concerns the gene CD274 and gastric cancer.